

Boston PD sample inquiry

Lab#	date recd	date analyzed	chemist	result reported	comment
	12/12/00	12/28/2000	ZYT	Reserpine	OK
	10/19/01	11/08/2001	ZYT	Verapamil	markings DAN 5600 Should be Trazadone
	10/24/02	11/19/2002	ZYT	Alprazolam	OK
	2/13/04	5/13/2004	KMC	Trihexylphenidate	OK
	12/13/00	1/09/2001	ZYT/PJP	Diazepam	OK
	3/23/01	4/10/2001	ZYT	Acetohexamide	markings DAN 5599 Should be Trazadone
	4/25/00	5/30/2000	ZYT/JD	Diazepam	OK
	12/29/00	2/05/2001	ZYT	Acetohexamide	markings DAN 5599 Should be Trazadone
	9/05/03	10/22/2003	MGL	Clonidine	OK
	12/09/04	2/07/2005	ZYT	Clomiphene	Blister pkg intact labeled Clomiphene
	9/19/01	10/05/2001	ZYT	Metoprolol	Marking M 321 listed in Micromedex as Lorazepam M 32 is Metoprolol
	9/27/02	10/29/2002	ZYT	Secobarb/Ephedrine	Markings 274-1 Blue Clonazepam by Micromedex search May have confused marking In DEA Drug Logo Index
	5/06/04	7/19/04	KMC/SJF	Alprazolam	OK

Check of tablet samples with markings (DAN 5599 and DAN 5600)

Tested by Appearance and Labeling by Zhi Tan

Included are analyses from.....1/12/2000---- 7/30/2004

Lab #	Markings	reported as	Correct I.D.	Date Analyzed
	DAN 5599	Trazodone	Trazodone	1/31/00
	DAN 5599	"	"	2/14/00
	DAN 5600	"	"	2/18/00
	DAN 5600	"	"	2/18/00
	DAN 5600	"	"	4/11/00
	DAN 5599	"	"	4/11/00
	DAN 5599	"	"	4/21/00
	DAN 5600	"	"	5/01/00
	DAN 5599	"	"	5/03/00
	DAN 5600	"	"	5/03/00
	DAN 5599	"	"	5/22/00
	DAN 5600	"	"	5/23/00
	DAN 5599	"	"	6/07/00
	DAN 5600	"	"	8/02/00
	DAN 5599	"	"	8/11/00
	DAN 5599	Acetohexamide	"	2/05/01 X
	DAN 5600	Trazodone	"	2/10/01
	DAN 5599	Acetohexamide	"	2/19/01 X
	DAN 5600	Verapamil	"	3/23/01 X
	DAN 5599	Acetohexamide	"	4/10/01 X
	DAN 5599	Acetohexamide	"	4/14/01 X
	DAN 5600	Verapamil	"	4/20/01 X
	DAN 5599	Acetohexamide	"	5/01/01 X
	DAN 5600	Verapamil	"	5/04/01 X
	DAN 5599	Acetohexamide	"	5/09/01 X
	DAN 5599	Acetohexamide	"	6/22/01 X
	DAN 5599	Acetohexamide	"	7/25/01 X
	DAN 5600	Trazodone	"	8/16/01
	DAN 5600	"	"	9/04/01
	DAN 5600	"	"	9/20/01
	DAN 5600	"	"	9/28/01
	DAN 5599	"	"	9/28/01
	DAN 5600	"	"	10/13/01
	DAN 5599	"	"	10/13/01
	DAN 5599	"	"	10/13/01
	DAN 5599	"	"	10/13/01
	DAN 5600	Verapamil	"	11/08/01 X
	DAN 5600	Verapamil	"	11/08/01 X

DAN 5600	Verapamil	“	11/14/01 X
DAN 5599	Acetohexamide	Trazodone	11/21/01 X
DAN 5599	Trazodone	“	1/17/02
DAN 5600	“	“	2/05/02
DAN 5599	“	“	2/08/02
DAN 5600	“	“	2/08/02
DAN 5600	“	“	2/08/02
DAN 5599	“	“	2/18/02
DAN 5600	“	“	3/05/02
DAN 5600	“	“	3/20/02
DAN 5600	“	“	3/20/02
DAN 5599	“	“	3/22/02
DAN 5600	“	“	4/17/02
DAN 5600	“	“	4/25/02
DAN 5599	“	“	4/25/02
DAN 5599	“	“	4/30/02
DAN 5600	“	“	4/30/02
DAN 5599	Acetohexamide	“	5/22/02 X
DAN 5600	Trazodone	“	6/06/02
DAN 5600	“	“	6/15/02
DAN 5599	“	“	6/23/02
DAN 5600	“	“	6/30/02
DAN 5599	“	“	9/12/02
DAN 5600	“	“	9/18/02
DAN 5600	“	“	9/25/02
DAN 5600	“	“	10/02/02
DAN 5599	“	“	10/02/02
DAN 5600	“	“	10/02/02
DAN 5599	“	“	10/09/02
DAN 5599	“	“	10/17/02
DAN 5599	“	“	12/17/02
DAN 5600	“	“	12/19/02
DAN 5599	“	“	12/19/02
DAN 5599	“	“	12/19/02
DAN 5600	“	“	12/19/02
DAN 5600	“	“	1/02/03
DAN 5599	“	“	1/04/03
DAN 5600	“	“	1/07/03
DAN 5599	“	“	1/10/03
DAN 5600	“	“	1/22/03
DAN 5600	“	“	3/15/03
DAN 5599	“	“	4/05/03
DAN 5599	“	“	4/05/03
DAN 5599	“	“	4/05/03
DAN 5599	“	“	4/28/03
DAN 5599	“	“	5/10/03

	DAN 5599	“	“	5/17/03
	DAN 5600	“	“	6/03/03
	DAN 5600	“	“	6/17/03
	DAN 5600	“	“	6/17/03
	DAN 5599	“	“	7/30/03
	DAN 5599	“	“	8/08/03
	DAN 5600	“	“	8/18/03
	DAN 5599	“	“	8/28/03
	DAN 5600	“	“	9/17/03
	DAN 5599	“	“	10/10/03
	DAN 5600	“	“	12/08/03
	DAN 5600	“	“	12/20/03
	DAN 5600	“	“	01/10/04
	DAN 5600	“	“	03/06/04
	DAN 5600	“	“	03/19/04
	DAN 5599	“	“	03/20/04
	DAN 5600	“	“	04/09/04
	DAN 5599	“	“	05/31/04
	DAN 5599	“	“	05/31/04
	DAN 5599	“	“	06/02/04
	DAN 5600	“	“	06/02/04
	DAN 5599	“	“	06/04/04
	DAN 5600	“	“	06/07/04
	DAN 5600	“	“	06/22/04
	DAN 5599	“	“	06/26/04
	DAN 5599	“	“	06/26/04
	DAN 5600	“	“	06/26/04

April 18, 2007

Sergeant Detective Courtney Matthews
Boston Police Department
One Schroeder Plaza
Boston, Ma. 02120

Dear Sergeant Matthews:

We have completed our audit of the Laboratory's analysis of the thirteen items, that you requested by letter dated March 19, 2007. The results of our audit revealed the following:

- 1) Items [REDACTED] were properly identified.
- 2) Items [REDACTED] consisting of tablets marked [REDACTED] were identified by appearance and labeling as containing the Class E drug Acetohexamide. However, our audit revealed that the tablets should have been identified as containing the Class E drug, Trazodone.
- 3) Item [REDACTED] consisting of tablets with the markings [REDACTED] were identified by appearance and labeling as containing the Class E drug, Verapamil. Our audit revealed that these tablets should also have been identified as containing the Class E drug, Trazodone.
- 4) Item [REDACTED] consisting of tablets marked [REDACTED] were identified by appearance and labeling as containing the Class E drug, Metoprolol. Our audit revealed that the tablets should have been reported as containing the Class C drug, Lorazepam.
- 5) Item [REDACTED] consisting of blue tablets marked [REDACTED] on one side and 1 on the other side were identified by appearance and labeling as containing Secobarbital and Ephedrine. We discovered several pharmaceuticals with similar markings. The laboratory would need to re-examine the tablets to verify the identity of the tablet submitted.

The Laboratory has determined that the following errors were made in the examination of four of the items by appearance and labeling.

Items [REDACTED]

The analyst made note that each item consisted of white tablets with the manufacturer's markings DAN/DAN on one side and [REDACTED] on the other side. When the analyst checked the markings in our Physicians Desk Reference (PDR) for Generic Drugs, 1997 edition, they mistakenly reported the findings for tablets with markings [REDACTED] Acetohexamide.

Item [REDACTED]

The analyst made note of six white tablets with manufacturer's markings DAN/DAN on one side and 5600 on the other. When the analyst checked the markings in the 1997 PDR for Generics, they mistakenly reported the findings for tablets with markings DAN/DAN 5601, Verapamil.

Item [REDACTED]

The analyst made note of 15 white tablets with manufacturer's markings of M on one side, and 321 on the other. When the analyst checked the markings in the reference guide, they mistakenly reported the results for tablets with the markings M 32, Metoprolol.

We believe that these errors were transcription errors made by one of our analysts. We are conducting a review of this analyst's work to determine if other errors may have occurred. Since 2003, we have been employing a computer search of tablet markings for the majority of Appearance and Labeling identifications, to better insure the accuracy of this process.

I hope this information is helpful in your current auditing process. The Department and I look forward to assisting you in the further auditing of analyzed items. If other possible errors are identified in your auditing, please alert us to this fact.

Sincerely,

Charles Salemi
Laboratory Supervisor
Department of Public Health
Drug Analysis Laboratory
305 South Street
Jamaica Plain, MA. 02130

cc: Dr. Alfred DeMaria
Julianne Nassif

